OTC: CLVLY - Clinuvel Pharmaceuticals Limited

半年間の収益性: -20.24%
セクタ: Healthcare

プロモーションスケジュール Clinuvel Pharmaceuticals Limited

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

さらに詳しく
The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

EBITDA 0.0168
EV/EBITDA 98.24
ISIN US1887691038
Industry Biotechnology
P/BV 29.78
P/E 93.89
P/S 54.84
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.031
Див.доход ао 0.3347
Дивиденд ао 0.0478
Сайт https://www.clinuvel.com
Цена ао 9.03
Число акций ао 0.05182 млрд
1日あたりの価格変動: +2.43% (7.81)
週ごとの価格変動: +6.81% (7.49)
月ごとの料金変更: -5.88% (8.5)
3ヶ月間の価格変動: -15.79% (9.5)
半年間の価格変動: -20.24% (10.03)
年間の価格変動: -27.67% (11.06)
3年間の価格推移: -61.56% (20.81)
5年間の価格推移: -70.15% (26.8)
年初からの価格変動: +3.36% (7.74)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 5.76 2
P/BV 2.5 6
P/E 14.26 8
EV/EBITDA 5.78 9
合計: 7.13

効率

名前 意味 学年
ROA, % 19.75 6
ROE, % 22.79 7
合計: 7.83

配当金

名前 意味 学年
Div yield, % 0.3469 0.88
DSI 1 10
合計: 3.63

義務

名前 意味 学年
Debt/EBITDA 0.0156 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 170.49 10
収益性 Ebitda, % 313.79 10
収益性 EPS, % 111.63 10
合計: 9.4
さらに詳しく

機関 音量 共有, %
Trust For Professional Managers-PMC Diversified Equity Fund 4782 0.01



スーパーバイザー 役職 支払い 生年
Dr. Philippe Jacques Wolgen M.B.A., M.D. CEO, MD & Director 1.86M 1963 (62 年)
Mr. Lachlan Hay Chief Operations Officer N/A
Mr. Malcolm Bull Head of Australian Operations & Investor Relations N/A
Dr. Rose Quadbeck-Diel Senior Vice President of Regulatory Affairs N/A
Dr. Azza Hamila Head of Quality Assurance & Drug Safety N/A
Dr. Dennis J. Wright BPharm, M.Sc., Ph.D. Chief Scientific Officer
Mr. Peter Vaughan Chief Financial Officer
Ms. Claire Newstead-Sinclair C.A. Company Secretary

住所: Australia, Melbourne. VIC, 535 Bourke Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.clinuvel.com